/ /

Mary Beth Nierengarten
New cytotoxic agents for prostate cancer on the horizon
Chicago—Although chemotherapy reigns supreme as the most effective systemic therapy to treat advanced prostate cancer, it is being contested with the rapid emergence and development of novel agents that are showing great promise in targeting pathways of cancer without causing damage to normal cells. However, it doesn't appear that chemotherapy will be relegated to the history books any time soon. Even if targeted therapies prove to be all they promise they may be, chemotherapy may still be essential.
Study of PE drug shows efficacy over placebo
Minneapolis—For men suffering from the most common sexual dysfunction, premature ejaculation, an investigational drug therapy may offer improved control over ejaculation and sexual satisfaction with a relatively low incidence of side effects.
'Significant' link found between ED, heart disease
San Antonio--Recently published prospective evidence strongly supports the growing recognition among physicians that erectile dysfunction may be a sign of future cardiovascular disease in some men.
Cryotherapy is a viable, minimally invasive option agaist aggressive tumors
Chicago--As the new horse at the track, cryotherapy is struggling to show its stride as a viable, effective treatment option for early prostate cancer.
Bracytherapy provides solid biochemical outcomes across all risk groups
Chicago--For early-stage prostate cancer, "brachytherapy has emerged as the weapon of choice," said Gregory Merrick, MD, of the Schiffler Cancer Center and Wheeling Jesuit University in West Virginia, in his opening remarks at the Windy City Shoot-Out here.
Antiandrogen plus LHRHa efficacious in advanced prostate cancer
Orlando, FL--The addition of the nonsteroidal antiandrogen bicalutamide (Casodex) to a luteinizing hormone-releasing hormone agonist (LHRHa) confers significant benefits over LHRH monotherapy as first-line treatment for advanced prostate cancer, according to a study presented by Japanese researchers at the American Society of Clinical Oncology annual meeting here.
Seeds, conformal proton beam treatment show similar results
Orlando, FL--In men with early-stage prostate cancer, permanent prostate seed implantation (PPI) appears to be as effective as high-dose conformal proton beam radiotherapy (CPBRT) in terms of biochemical control and reduction of PSA levels, according to findings from a new study.
ADT-chemo combo cuts time to progression in PCa
Orlando, FL--Recent preclinical evidence now suggests that administering androgen deprivation therapy (ADT) concurrently with paclitaxel (Taxol) is more effective than sequential treatment in androgen-dependent prostate cancer. In a study presented at the 2005 American Society of Clinical Oncology annual meeting, both time to tumor progression and time to sacrifice were significantly improved in mice treated with the combination therapy compared with sequential therapy.
Older, sicker men receive ADT for localized prostate Ca
Orlando, FL--Men with localized prostate cancer who are treated with primary androgen deprivation therapy tend to be older and to have more comorbidities and lower incomes than men treated by other primary therapies, according to a study presented at the 2005 American Society of Clinical Oncology meeting.

Poll